亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 伊馬替尼中間體CAS號: 152460-10-1
伊馬替尼中間體CAS號: 152460-10-1
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 152460-10-1
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶
CAS號: 152460-10-1
中文同義詞: N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶;N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺;N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶,伊馬替尼中間體(伊馬胺);N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶,伊馬替尼中間體;伊馬替尼中間體
英文名稱: N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine
英文同義詞: 4-Methyl-N'-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine;4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]aniline;n-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine;N-(2-Methyl-5-Amino Phenyl)-4-(3-Pyridyl)-2-Pyrimidine;4-Methyl-N3-[4-(3-Pyridinyl)-2-Pyrimidinyl]-1,3-Benzenediamine;N-(5-amino-2-methylphenyl)-4-(3-pyridinyl)-2-pydimidineamine;1,3-BENZENEDIAMINE,4-METHYL-N3-[4-(3-PYRIDINYL)-2-PYRIMIDINYL]-;6-Methyl-n1-[4-(pyridine-3-yl)pyrimidin-2-yl]benzene-1,3-diamine
分子式: C16H15N5
分子量: 277.32
標準:企業標準
含量:≥98.5%
性狀;白色粉末
用途  伊馬替尼中間體
包裝;1kg/鋁箔袋
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31096  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |